.
SYNGENE financial statements
* Numbers in millions
| Capitalization * | 230 203 |
|---|---|
| EV * | 225 949 |
| Number of shares * | 398 |
| EPS | 10,18 |
| Revenue * | 20 891 |
| Net income * | 4 049 |
| Operating profit * | 3 877 |
| Total liabilities * | 20 618 |
| Net debt * | 5 709 |
| Total assets * | 48 832 |
| Equity * | 28 214 |
| Cash and investments * | 7 897 |
.
SYNGENE valuation
| P/E | 56,85 |
|---|---|
| P/B | 8,16 |
| P/S | 11,02 |
| E/P | 2 |
| P/FCF | 90,38 |
.
SYNGENE profitability
| ROE | 14% |
|---|---|
| ROA% | 8% |
| ROIC% | 10% |